Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Finished Goods (2016 - 2018)

Vanda Pharmaceuticals' Finished Goods history spans 5 years, with the latest figure at $1.0 million for Q1 2018.

  • For Q1 2018, Finished Goods rose 31.98% year-over-year to $1.0 million; the TTM value through Mar 2018 reached $1.0 million, up 31.98%, while the annual FY2017 figure was $760000.0, 0.26% changed from the prior year.
  • Finished Goods for Q1 2018 was $1.0 million at Vanda Pharmaceuticals, up from $760000.0 in the prior quarter.
  • Across five years, Finished Goods topped out at $3.4 million in Q4 2014 and bottomed at $611000.0 in Q2 2017.
  • The 5-year median for Finished Goods is $941000.0 (2014), against an average of $1.5 million.
  • The largest YoY upside for Finished Goods was 181.19% in 2015 against a maximum downside of 61.87% in 2015.
  • A 5-year view of Finished Goods shows it stood at $3.4 million in 2014, then plummeted by 61.87% to $1.3 million in 2015, then tumbled by 41.11% to $762000.0 in 2016, then fell by 0.26% to $760000.0 in 2017, then soared by 33.03% to $1.0 million in 2018.
  • Per Business Quant, the three most recent readings for VNDA's Finished Goods are $1.0 million (Q1 2018), $760000.0 (Q4 2017), and $858000.0 (Q3 2017).